Company Profile for Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze(TM) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche to apply Enhanze Technology to Roche's biological therapeutics for up to 13 targets and with Baxter BioScience to apply Enhanze Technology to Baxter's biological therapeutic compound, GAMMAGARD LIQUID. Halozyme's research pipeline candidates target significant areas of unmet medical need.

                       <

Company:               <
Halozyme Therapeutics, Inc.
                       <

Headquarters Address:  <
11388 Sorrento Valley Road
                       <
San Diego, CA 92121
                       <

Main Telephone:        <
858-794-8889
                       <

Website:               <
www.halozyme.com
                       <

Ticker:                <
HALO(NASDAQ)
                       <

Type of Organization:  <
Public
                       <

Industry:              <
Biotechnology
                       <

Key Executives:        <
CEO: Jonathan Lim, M.D.
                       <

Investor Relations     <

Contact:               <
Robert Uhl
Phone:                 <
858-704-8264
Email:                 <
[e-mail]